Wedbush downgraded Alto Neuroscience (ANRO) to Neutral from Outperform with a price target of $4, down from $29.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANRO:
- Alto Neuroscience downgraded to Neutral from Buy at Rodman & Renshaw
- Alto Neuroscience price target lowered to $10 from $32 at Baird
- Alto Neuroscience CEO says ‘strong cash balance to support us’
- Alto Neuroscience falls 47% after announcing ALTO-100 did not meet endpoint
- Alto Neuroscience’s Phase 2b study of ALTO-100 did not meet primary endpoint